{"analyses":[{"ciLowerLimit":"32.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"46.0","estimateComment":"The adjusted difference and its 95% CI were calculated using the Wald method from Cochran-Mantel Haenszel test to account for the randomization schedule stratification factors.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.001","pValueComment":"p-value was calculated from a stratified Cochran-Mantel Haenszel test accounting for the randomization schedule stratification factors.","paramType":"Adjusted difference","paramValue":"39.4","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.9","upperLimit":"60.1","value":"55.5"},{"groupId":"OG001","lowerLimit":"11.6","upperLimit":"21.5","value":"16.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"description":"DCR was defined as percentage of participants achieving a best overall response of confirmed CR, PR, or stable disease (SD) (for at least 7 weeks) per RECIST v1.1, as determined by the investigator. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until the first documentation of best overall response (up to 22 months)","title":"Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}